Clinical Research Directory

Key Inclusion Criteria: * Rollover participants have completed either parent study BHV1300-202 or BHV1300-302. * De novo Participants must have: * Serologically confirmed Graves' disease as documented by presence of elevated antibodies * Active hyperthyroidism due to Graves' disease Key Exclusion Criteria: * Rollover participants must not have met early termination criteria in the parent study * De novo participants Key Exclusion: * History of hyperthyroidism not caused by Graves' Disease (e.g., toxic adenoma or toxic multinodular goiter) * Have received levothyroxine, desiccated thyroid extract, or T3 at any dose within six weeks of the Baseline/Day 1 visit. * Thyroid storm, i.e. severe thyrotoxicosis with evidence of systemic decompensation (e.g., Burch-Wartkofsky Point Scale of ≥ 45 or Japanese Thyroid Association category 1 or 2, with accompanying manifestations including hyperpyrexia, tachycardia, arrhythmias, congestive heart failure, agitation, delirium, psychosis, stupor, and coma, as well as nausea, vomiting, diarrhea, or hepatic failure) within 6 weeks of Screening * Have autoimmune disease other than Graves' disease requiring treatment * Have moderate to severe thyroid eye disease (TED) or are expected to require immediate surgical intervention and/or are planning corrective surgery/irradiation or medical therapy for TED during study participation. * Are expected to require urgent or emergent thyroid surgery or ablation within six weeks of Baseline/Day 1 or throughout the study.